- Side Effects
- Drug Interaction
What is Afluria Quadrivalent (Influenza Vaccine), and how does it work?
Generic drug: Influenza Vaccine
Brand name: Afluria Quadrivalent
Afluria Quadrivalent (Influenza Vaccine) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Afluria Quadrivalent is approved for use in persons 18 years of age and older.
What are the side effects of Afluria Quadrivalent?
In adults 18 through 64 years of age, the most commonly reported injection-site adverse reaction observed in clinical studies with Afluria Quadrivalent administered by needle and syringe was pain (≥40%).
The most common systemic adverse events observed were
In adults 65 years of age and older, the most commonly reported injection-site adverse reaction observed in clinical studies with Afluria Quadrivalent administered by needle and syringe was pain (≥20%).
The most common systemic adverse event observed was
- myalgia (≥10%).
The safety experience with Afluria (trivalent formulation) is relevant to Afluria Quadrivalent because both vaccines are manufactured using the same process and have overlapping compositions.
In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions observed in a clinical study with Afluria (trivalent formulation) using the PharmaJet Stratis Needle-Free Injection System were
The most common systemic adverse events were
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to rates in the clinical studies of another vaccine and may not reflect the rates observed in clinical practice.
- Clinical safety data for Afluria Quadrivalent have been collected in one clinical trial, Study 1, a randomized, double-blind, active-controlled trial conducted in the US in 3449 subjects ages 18 years and older.
- Subjects in the safety population received one dose of either Afluria Quadrivalent (N=1721) or one of two formulations of comparator trivalent influenza vaccine (Afluria, TIV-1 N=864 or TIV-2 N=864) each containing an influenza type B virus that corresponded to one of the two B viruses in Afluria Quadrivalent (a type B virus of the Yamagata lineage or a type B virus of the Victoria lineage), respectively.
- The mean age of the population was 58 years, 57% were female, and racial groups consisted of 82% White, 16% Black, and 2% other; 5% of subjects were Hispanic/Latino.
- The age sub-groups were 18 through 64 years and 65 years and older with mean ages of 43 years and 73 years, respectively. In this study, Afluria Quadrivalent and comparator trivalent influenza vaccines were administered by needle and syringe.
- Local (injection-site) adverse reactions and systemic adverse events were solicited for 7 days post-vaccination (Table 1).
- Injection site cellulitis, cellulitis-like reactions (defined as concurrent Grade 3 pain, redness, and swelling/lump), and Grade 3 swelling/lump were monitored for 28 days post-vaccination.
- Unsolicited adverse events were collected for 28 days post-vaccination. Serious adverse events (SAEs), including deaths, were collected for 180 days post-vaccination.
Table 1: Proportion of Subjects Per Age Cohort with Any Solicited Local Adverse Reactions or Systemic Adverse Events within 7 Days after Administration of
Afluria Quadrivalent or Trivalent Influenza Vaccine (Study 1)a
|Percentage (%) b of Subjects in each Age Cohort Reporting an Event|
|Subjects 18 through 64 years||Subjects ≥ 65 years|
N= 854 c
N= 428 c
N= 430 c
N= 867 c
N= 436 c
N= 434 c
|Any||Gr 3||Any||Gr 3||Any||Gr 3||Any||Gr 3||Any||Gr 3||Any||Gr 3|
|Local dverse Reactions d|
|Systemic Adverse Events e|
|Myalgia (muscle ache)||25.5||1.9||23.4||1.4||24.2||1.2||12.7||0.3||14.0||0.7||12.2||0.5|
|Abbreviations: Gr 3, Grade 3.
b Proportion of subjects reporting each solicited local adverse reaction or systemic adverse event by study vaccine group based on the number of subjects contributing any follow up safety information for at least one data value of an individual sign/symptom.
c N = number of subjects in the Safety Population for each study vaccine group.
d Local adverse reactions: Grade 3 pain is that which prevents daily activity; Swelling/Lump and redness: any = ≥ 20mm diameter, Grade 3 = ≥ 100mm diameter.
e Systemic adverse events: Fever: any = ≥ 100.4°F, Grade 3 = ≥ 102.2°F; Grade 3 for all other adverse events is that which prevents daily activity.
- In the 28 days following vaccination, no subject experienced cellulitis or a cellulitis-like reaction. All Grade 3 swelling/lump reactions began within 7 days of vaccination and are included in Table 1.
- In the 28 days following vaccination, 20.5%, 20.1%, and 20.7% of adults 18 through 64 years and 20.3%, 24.1%, and 20.0% of adults ≥65 years who received Afluria Quadrivalent , TIV-1, and TIV-2, respectively, reported unsolicited adverse events. Rates of individual events were similar between treatment groups, and most events were mild to moderate in severity.
- In the 180 days following vaccination, 2.3%, 1.6%, and 1.5% of all subjects who received Afluria Quadrivalent , TIV-1, and TIV-2, respectively, experienced SAEs, including six deaths, five in the Afluria Quadrivalent group and one in the TIV-2 group. The majority of SAEs occurred after Study Day 28 and in subjects ≥65 years of age who had co-morbid illnesses. No SAEs or deaths appeared related to the study vaccines.
- Safety information has also been collected in a clinical study of Afluria (trivalent formulation) administered using the PharmaJet Stratis Needle-Free Injection System (Study 2).
- Study 2 included 1,247 subjects for safety analysis, ages 18 through 64 years, randomized to receive Afluria by either the PharmaJet Stratis Needle-Free Injection System (624 subjects) or needle and syringe (623 subjects).
- No deaths or vaccine-related serious adverse events were reported in Study 2. Local (injection-site) adverse reactions and systemic adverse events were solicited for 7 days post-vaccination (Table 2).
Table 2: Proportion of Subjects 18 through 64 Years of Age with Solicited Local Adverse Reactions or Systemic Adverse Events within 7 Days after Administration of
Afluria (trivalent formulation) by PharmaJet Stratis Needle-Free Injection System or Needle and Syringe (Study 2)a
|Percentage b of Subjects Reporting Event|
Subjects 18 through 64 years
|Afluria (trivalent formulation)|
|PharmaJet Stratis Needle-Free Injection System
|Needle and Syringe
|Any||Grade 3||Any||Grade 3|
|Local Adverse Reactions d|
|Systemic Adverse Events e|
b Proportion of subjects reporting each local adverse reaction or systemic adverse event by treatment group based on the number of subjects contributing at least one data value for an individual sign/symptom (individual event denominators).
c N = number of subjects in the Safety Population for each treatment group. Denominators for the PharmaJet Stratis Needle-Free Injection System group were: N=540 for itching and N=605-616 for all other parameters. Denominators for the needle and syringe group were: N=527 for itching and N=599-606 for all other parameters.
d Local adverse reactions: Grade 3 is pain, tenderness or itching that prevents daily activity; Swelling, redness or bruising: any = ≥ 25mm diameter, Grade 3 = > 100mm diameter.
e Systemic adverse events: Fever: any = ≥ 100.4°F, Grade 3 = ≥ 102.2°F; Grade 3 for all other adverse events is that which prevents daily activity.
f A total of 155 subjects (approximately randomly distributed between PharmaJet Stratis Needle-Free Injection System and needle and syringe groups) received Diary Cards without itching listed as a solicited symptom.
In adults 18 through 64 years who received Afluria (trivalent formulation) administered via PharmaJet Stratis Needle-Free Injection System, commonly reported unsolicited adverse events were
- headache (4.2%),
- injection site hematoma (1.8%),
- injection site erythema (1.1%),
- myalgia (1.0%) and
- nausea (1.0%).
Because postmarketing reporting of adverse events is voluntary and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. The adverse events described have been included in this section because they:
- 1) represent reactions that are known to occur following immunizations generally or influenza immunizations specifically;
- 2) are potentially serious; or
- 3) have been reported frequently.
There are no postmarketing data available for Afluria Quadrivalent . The adverse events listed below reflect experience in both children and adults and include those identified during post-approval use of Afluria (trivalent formulation) outside the US since 1985.
The post-marketing experience with Afluria (trivalent formulation) included the following:
Blood And Lymphatic System Disorders
Immune System Disorders
Nervous System Disorders
- Neuralgia, paresthesia, convulsions (including febrile seizures), encephalomyelitis, encephalopathy, neuritis or neuropathy, transverse myelitis, and GBS
- Vasculitis which may be associated with transient renal involvement
Skin And Subcutaneous Tissue Disorders
General Disorders And Administration Site Conditions
- Cellulitis and large injection site swelling
- Influenza-like illness
What is the dosage for Afluria Quadrivalent?
For Intramuscular (IM) Use Only.
- By needle and syringe (18 years of age and older)
- By PharmaJet Stratis Needle-Free Injection System (18 through 64 years of age)
Administer as a single 0.5 mL dose.
Immediately before use, shake thoroughly and inspect visually. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever suspension and container permit. If either of these conditions exists, the vaccine should not be administered.
The preferred site for intramuscular injection is the deltoid muscle of the upper arm.
When using the multi-dose vial, shake the vial thoroughly before withdrawing each dose.
It is recommended that small syringes (0.5 mL or 1 mL) be used to minimize any product loss.
To use the PharmaJet Stratis Needle-Free Injection System, refer to the Instructions for Use for the PharmaJet Stratis Needle-Free Injection System.
What drugs interact with Afluria Quadrivalent?
Is Afluria Quadrivalent safe to use while pregnant or breastfeeding?
- All pregnancies have a risk of birth defect, loss, or other adverse outcomes.
- In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
- There are no data for Afluria Quadrivalent administered to pregnant women to inform vaccine-associated risks in pregnancy.
- Available data on Afluria (trivalent formulation) administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.
- It is not known whether Afluria Quadrivalent is excreted in human milk.
- Data are not available to assess the effects of Afluria Quadrivalent on the breastfed infant or on milk production/excretion.
Latest Cold and Flu News
Daily Health News
Afluria Quadrivalent (Influenza Vaccine) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Afluria Quadrivalent is approved for use in persons 18 years of age and older. In adults 18 through 64 years of age, the most commonly reported injection-site adverse reaction observed in clinical studies with Afluria Quadrivalent administered by needle and syringe was pain (=40%). The most common systemic adverse events observed were myalgia and headache.
Multimedia: Slideshows, Images & Quizzes
Cold, Flu, and Cough: 13 Foods to Eat When Fighting the Flu
The best foods to eat when you have the flu soothe symptoms and help you feel better faster. Good foods to eat with the flu...
Cold, Fever and Flu Treatment in Children: Medications and Home Remedies
Colds and fevers are some of the most common ailments in children. Learn common cold symptoms, treatment options, over the...
Cold and Flu: Finding Relief for Your Cough
Remedies for coughing to relieve symptoms, thin mucus, and clear phlegm include cough syrup and honey in hot water. Use...
Natural Remedies for Cold and Flu
What natural remedies work for the flu and common cold? Many claim cold symptoms and flu symptoms can be relieved with Echinacea,...
10 Facts About Flu Shots
Is the flu shot necessary? Who should get vaccinated? Learn the benefits and risks of vaccination for seasonal influenza. Find...
A Cold or The Flu? How to Tell the Difference
Learn common symptoms of a cold and the flu. Discover the difference between a cold and the flu. Read about cold and flu...
Cold & Flu Quiz: Influenza vs. Common Cold
Aches? Pain? Fever? This Cold & Flu Quiz tests your knowledge on the difference between coming down with the common cold and...
Home Remedies for Sick Children
Home remedies for kids can help with things like colds, flu, cough, sore throat, stuffy nose, fever, and upset stomach. Eating...
Germs: Everyday Items with the Most Bacteria
Explore the germiest places you may encounter daily. Bacteria is everywhere. Learn tips to avoid germs and bacteria in public...
Cold and Flu: The Truth About Hand Sanitizer
Hand sanitizers are a convenient way to kill germs. But do they really work? Here's what we found.
Related Disease Conditions
Bird Flu (Avian Influenza, Avian Flu)
Bird flu (avian flu, avian influenza) infection in humans may result from contact with infected poultry. There is a vaccine to prevent human infection with the H5N1 strain of the avian flu virus.
COVID-19 vs. Flu vs. Cold
When you're feeling sick, it can be difficult to distinguish the symptoms of a COVID-19 infection from the symptoms of the common cold or the flu (influenza). While fever is common with the flu and COVID-19, sneezing is typically only associated with colds. Though sore throats are typical with colds, they are uncommon with COVID-19 infections and the flu.
Influenza (flu) is a respiratory illness caused by a virus. Flu symptoms include fever, cough, sore throat, runny nose, headache, fatigue, and muscle aches. The flu may be prevented with an annual influenza vaccination.
How Long Is a Cold or Flu Contagious?
Viruses cause the common cold and the flu. Early symptoms and signs for a cold and the flu are similar, however, flu symptoms are typically more severe than cold symptoms. Cold and flu viruses are transmitted typically via coughing or sneezing.
Diabetes and Safe Medications for Colds and the Flu: OTC Medication Guide
If you have diabetes and catch a cold or the flu, can be more difficult to recover from infections and their complications, for example, pneumonia. Home remedies and over-the-counter (OTC) drugs used for the treatment of the signs and symptoms of colds and the flu may affect blood sugar levels in people with diabetes.Some medications are OK to take if you have diabetes get a cold or the flu include nonsteroidal anti-inflammatory drugs or NSAIDs, like acetaminophen (Tylenol) and ibuprofen (Motrin) to control symptoms of fever and pain. Most cough syrups are safe to take; however, check with your pediatrician to see what medications are safe to give your child if he or she has type 1 or 2 diabetes. If you have diabetes and are sick with a cold or flu, you need to check your blood sugar levels more frequently. Continue taking your regular medications. Eat a diabetic low-glycemic index diet rich in antioxidants. To prevent colds and the flu drink at least eight 8 ounce glasses of water a day. To replenish fluids, drink sports drinks like Gatorade and Pedialyte to replenish electrolytes. Avoid people who are sick, sneezing, coughing, or have other symptoms of a cold or flu.
Is Swine Flu (H1N1) Contagious?
Swine flu (H1N1) is a contagious virus that spreads when an infected individual expels virus-containing droplets into the air during coughing or sneezing. Symptoms include sore throat, runny nose, fever, cough, chills, headache, fatigue, and possible vomiting and/or diarrhea. An H1N1 infection typically lasts for about a week.
Pregnancy: Swine Flu and the H1N1 Vaccine
Pregnant and women who are breastfeeding are encouraged to receive the seasonal flu shot as well as the 2009 H1N1 influenza (swine flu) vaccine. H1N1 flu is treated with the medications Tamiflu® (oseltamivir) or Relenza® (zanamivir). Pregnant women should not receive the H1N1 attenuated nasal spray vaccine. Possible side effects of the H1N1 flu vaccine include muscle aches, fever, nausea, tiredness, or headache.
Treating the Flu in People with Health Risks
Certain portions of the population are at an increased risk of suffering serious complications from the flu. Some of these indviduals at risk include: those with asthma, COPD, heart disease, liver or kidney disease, HIV, AIDs, elderly, women who are pregnant, and children under the age of two. Contact your physician if you have the flu immediately so that you receive the proper care to prevent serious complications.
How Long Does the Flu Last in Seniors?
What is the flu? Learn the signs of the flu in seniors and when you need to call a doctor.
How Long Do Flu Symptoms Last in Toddlers?
What is the flu, and how long do symptoms last in kids? Learn the signs of the flu and find out what medicines may help.
How Do You Cure the Flu Quickly?
Flu or influenza is a common viral disease affecting the respiratory system. This infectious disease is caused by the influenza virus. Most cases of flu are self-limiting and can be easily managed at home.
Treatment & Diagnosis
- Cold & Flu FAQs
- Tamiflu for Bird Flu?
- Nasal Flu Vaccine for Children
- Flu: Waiting for Flu Shots, a Real Reality Show
- Flu Shot Fiasco, Critical Incident Report
- Swine Flu Symptoms, Diagnosis, and Vaccination
- What to Do if You Think You Have H1N1 Swine Flu Virus
- H1N1 Swine Flu Can Infect Some Pets
- Flu Shot Side Effects
- Will a Flu Shot Prevent Pleurisy?
- Flu Shots - Next Big Influenza Outbreak
- Bird Flu: What Is Bird Flu? Should We Be Concerned?
- Flu Free: How to Fend Off the Flu
Medications & Supplements
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.